Hormone therapy after the FDA's 2025 change
For more than twenty years, a black box warning scared many women away from hormone therapy. In November 2025 the FDA began removing it. Here's what changed, what didn't, and what it means for you.
The short answer: on November 10, 2025, the FDA announced it was removing the boxed warnings about heart disease, breast cancer and probable dementia from menopause hormone therapy, and asked for labels to include age-specific guidance. The warning about endometrial cancer stays on systemic estrogen-only products. For most healthy women under 60, or within 10 years of menopause, the benefits of hormone therapy outweigh the risks.
If you were told years ago that hormones were dangerous, or you stopped them in a hurry after the headlines, this is worth revisiting with a clinician who knows your history.
How we got here
In 2002, the Women's Health Initiative (WHI) stopped its trial of combined estrogen and progestin early, reporting small increases in breast cancer, heart disease, stroke and blood clots. The news made headlines around the world, prescriptions fell sharply, and a boxed warning, the FDA's strongest, went on every estrogen product.
What got lost was who was studied. The average woman in the WHI was 63, many years past menopause, and few had significant hot flashes. That's a very different group from the women in their late 40s and early 50s who usually start hormone therapy for symptoms.
Over the following two decades, re-analysis of the same data and new studies showed that timing matters. Started closer to menopause, hormone therapy carries lower risks, and for some outcomes the balance looks favorable. Guidance from the Menopause Society shifted to reflect that years ago. The FDA's 2025 decision brings the product labels in line.
What changed
- Boxed warnings about heart disease, breast cancer and probable dementia are being removed
- Labels will include age-specific guidance, noting benefits for women who start within 10 years of menopause
- The change covers low-dose vaginal estrogen too, which had carried the same warnings
- Label updates roll out over the months following the announcement
What didn't
- The endometrial cancer warning stays on systemic estrogen-only products, which is why women with a uterus also take progesterone
- Hormone therapy is still not recommended after breast or uterine cancer, a blood clot, stroke or heart attack, or with active liver disease
- Risk still depends on your age, timing, dose and type of hormone
- Hormone therapy is still not a treatment to prevent heart disease or dementia
A 2002 headline shouldn't make your decision.
Most new patients are seen within a week, in person in Bridgewater or Nutley, or by video anywhere in New Jersey.
What the evidence says about the big worries
- Breast cancer: combined estrogen and progestin used for several years is linked to a small increase in risk. Estrogen alone, for women who have had a hysterectomy, was not linked to an increase in the WHI. Your personal and family history matter most here.
- Heart disease: for women who start near menopause, hormone therapy does not appear to raise heart risk the way the early headlines suggested. Starting many years later is a different story.
- Blood clots and stroke: the risk is real but small, and lower with estrogen through the skin (a patch, gel or spray) than with pills. Patch vs. pill vs. cream
- Dementia: the earlier warning came from women who started hormones at 65 or older. Hormone therapy isn't used to prevent dementia, but the warning no longer applies across the board.
What it means for you
If hot flashes, night sweats, poor sleep or vaginal dryness are affecting your life, hormone therapy deserves a fair hearing. At our clinic that means a real conversation about your symptoms, your personal and family history, and your preferences, followed by a choice of dose and form that fits you, and a yearly review.
If hormones aren't right for you, there are good alternatives. Non-hormonal treatment
Keep reading
Questions about the FDA change
Did the FDA remove the black box warning on HRT?
Yes, in part. On November 10, 2025, the FDA announced it was removing the boxed warnings about heart disease, breast cancer and probable dementia from menopause hormone therapy products and asked manufacturers to update their labels. The boxed warning about endometrial cancer stays on systemic estrogen-only products.
Does this mean HRT is completely safe now?
No medicine is risk-free. The change reflects evidence that for most healthy women who start hormone therapy before 60, or within 10 years of menopause, the benefits outweigh the risks. Your own history still matters, and some women still shouldn't take it.
Why was the warning there in the first place?
It was added after the Women's Health Initiative study in 2002. That study mainly enrolled women in their 60s and 70s, many years past menopause, which is not the group who usually starts hormones for symptoms. Later analyses showed the risks look quite different for younger women who start earlier.
Does the change apply to vaginal estrogen?
Yes. The FDA's action covered menopause hormone therapy products broadly, including low-dose vaginal estrogen, which had carried the same boxed warnings despite very little of it reaching the rest of the body.
I stopped HRT years ago because of the warnings. Should I restart?
It's worth a conversation. If you still have bothersome symptoms and you're within the age and timing window where benefits usually outweigh risks, hormone therapy may be a reasonable option. We'll go through your history before recommending anything.
- U.S. Food and Drug Administration. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. November 10, 2025.
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2022;29(7):767–794.
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288(3):321–333.
Contact MyPremierMD Today
We'll reach out within 24 hours to answer your questions and help you schedule an appointment.